Key facts
- KORTUC’s last known valuation is $281.4M (Nov 2021).
- It has raised $44.4M; the latest was Later Stage VC ($20.0M) in Aug 2025.
- Notable investors include SBI Investment, Nissay Capital, Pegasus Tech Ventures, Loyal VC, AXA Japan — 11 tracked in total.
- KORTUC has filed 1 Form D with the SEC, most recently Nov 2023 ($3K sold to 1 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for KORTUC
- ·The full record, as it builds
Funding rounds
No funding rounds for KORTUC are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KORTUC
Developer of a novel radiosensitizer designed to enhance the efficacy of cancer radiotherapy. The company develops hydrogen peroxide-based drugs delivered via a prefilled syringe, injected intratumorally before radiotherapy to make hypoxic tumors responsive to radiation by inactivating antioxidative enzymes, enabling medical professionals to control the radiated tumors and improve the efficacy of radiation therapy.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2015
- Employees
- 3
- Website
- kortuc.com/
- Ownership
- Privately Held (backing)
KORTUC doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KORTUC shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KORTUC in its N-PORT filings yet. We sweep new filings monthly.